Roche has announced the US launch of automated Elecsys HE4 assay, designed as an aid in monitoring the recurrence or progressive disease in patients with epithelial ovarian cancer.
The assay, which is approved for use on the Elecsys 2010, cobas e 411, cobas e 601, cobas e 602 andMODULAR ANALYTICS E170 analyzers, is used for the quantitative determination of HE4 in human serum and plasma.
In addition, the assay uses the company’s electrochemiluminescence technology, designed to provide excellent low-end sensitivity and broad dynamic measuring ranges.
Studies like K Huhtinen et al (2009) have demonstrated that HE4 shows a high specificity to ovarian cancer over that of CA 125 alone.
Roche Diagnostics marketing vice president Randy Pritchard said the company is committed to provide oncology diagnostic tests to deliver the best possible care to their patients.
"The addition of the Elecsys HE4 assay further strengthens our tumor biomarker menu and means healthcare providers now have another tool to give them greater confidence in monitoring patients with ovarian cancer," Pritchard added.